Cargando…
Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations
Emerging data from global markets outside the United States, where many generic iron sucrose formulations are available, have revealed that non‐US generic intravenous (i.v.) iron formulations may have iron release profiles that differ from the reference listed drug (RLD). The first generic i.v. iron...
Autores principales: | Pai, AB, Meyer, DE, Bales, BC, Cotero, VE, Pai, MP, Zheng, N, Jiang, W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421824/ https://www.ncbi.nlm.nih.gov/pubmed/28160427 http://dx.doi.org/10.1111/cts.12443 |
Ejemplares similares
-
Mitochondria-penetrating peptides conjugated to desferrioxamine as chelators for mitochondrial labile iron
por: Alta, Roxana Y. P., et al.
Publicado: (2017) -
Ferrous iron content of intravenous iron formulations
por: Gupta, Ajay, et al.
Publicado: (2016) -
Iron infusion and newer intravenous iron formulations
por: Aung, Tim, et al.
Publicado: (2021) -
Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia
por: Daar, Shahina, et al.
Publicado: (2009) -
Iron Chelators in Treatment of Iron Overload
por: Entezari, Sarina, et al.
Publicado: (2022)